With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...

Biopharmaceuticals stock Gilead Sciences (NASDAQ: GILD) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...

Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate settlement with Gilead Sciences, Inc. over an illegal kickback scheme to ...

After purging the CDC’s vaccine advisory committee and replacing it with his own appointments, U.S. Health Secretary Robert F ...

Gilead Contacts: Jacquie Ross, Investors (650) 425-8408 Mark Snyder, Media (650) 446-6957 Gritstone Contacts: Alexandra Santos, Investors (510) 871-6161 Dan Budwick, Media (973) 271-6085 ...

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.